- Markets
- Healthcare
- KREBSBIO
KREBSBIO
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Krebs Biochemicals And Industries Says Pabitrakumar Kalipada Bhattacharya Resigns As MD
Aug 9 (Reuters) - Krebs Biochemicals and Industries Ltd KREB.NS:
PABITRAKUMAR KALIPADA BHATTACHARYA RESIGNS AS MD
APPOINTS JITENDRA SHAH AS MD,CEO
Source text for Eikon: ID:nBSE6QQ4zr
Further company coverage: KREB.NS
(([email protected];))
Aug 9 (Reuters) - Krebs Biochemicals and Industries Ltd KREB.NS:
PABITRAKUMAR KALIPADA BHATTACHARYA RESIGNS AS MD
APPOINTS JITENDRA SHAH AS MD,CEO
Source text for Eikon: ID:nBSE6QQ4zr
Further company coverage: KREB.NS
(([email protected];))
Events:
Rights
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Krebs Biochem.&Inds do?
Krebs Biochemicals & Industries Limited is an India-based pharmaceutical company specializing in fermentation technology. They produce products like lavastatin and simvastatin.
Who are the competitors of Krebs Biochem.&Inds?
Krebs Biochem.&Inds major competitors are Panchsheel Organics, Kimia Biosciences, Denis Chem Lab, Vaidya Sane Ayur Lab, Murae Organisor, Alpa Lab, Bharat Immunological. Market Cap of Krebs Biochem.&Inds is ₹171 Crs. While the median market cap of its peers are ₹144 Crs.
Is Krebs Biochem.&Inds financially stable compared to its competitors?
Krebs Biochem.&Inds seems to be less financially stable compared to its competitors. Altman Z score of Krebs Biochem.&Inds is -1.08 and is ranked 8 out of its 8 competitors.
Does Krebs Biochem.&Inds pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Krebs Biochem.&Inds latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Krebs Biochem.&Inds allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Krebs Biochem.&Inds balance sheet?
Krebs Biochem.&Inds balance sheet is weak and might have solvency issues
Is the profitablity of Krebs Biochem.&Inds improving?
The profit is oscillating. The profit of Krebs Biochem.&Inds is -₹24.52 Crs for TTM, -₹19.75 Crs for Mar 2024 and -₹24.37 Crs for Mar 2023.
Is the debt of Krebs Biochem.&Inds increasing or decreasing?
Yes, The debt of Krebs Biochem.&Inds is increasing. Latest debt of Krebs Biochem.&Inds is ₹204 Crs as of Sep-24. This is greater than Mar-24 when it was ₹193 Crs.
Is Krebs Biochem.&Inds stock expensive?
There is insufficient historical data to gauge this. Latest PE of Krebs Biochem.&Inds is 0
Has the share price of Krebs Biochem.&Inds grown faster than its competition?
Krebs Biochem.&Inds has given lower returns compared to its competitors. Krebs Biochem.&Inds has grown at ~-21.64% over the last 3yrs while peers have grown at a median rate of -4.34%
Is the promoter bullish about Krebs Biochem.&Inds?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Krebs Biochem.&Inds is 72.74% and last quarter promoter holding is 72.74%.
Are mutual funds buying/selling Krebs Biochem.&Inds?
There is Insufficient data to gauge this.